Oral testosterone replacement in symptomatic late-onset hypogonadism: Effects on rating scales and general safety in a randomized, placebo-controlled study

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 821-831

  Legros, Jean Jacques ^a   Meuleman, Eric J H ^b   Elbers, Jolanda M H ^c   Geurts, T B Paul ^d   Kaspers, Marion J G H ^e   Bouloux, Pierre M G ^f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Global Clinical Research   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Research Data and Quantitative Sciences   (Netherlands)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDRIOL TESTOCAPS; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANDROGEN THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EUROPE; EVENING DOSAGE; FATIGUE; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTENSION; HYPOGONADISM; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SEXUAL FUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN; AGED; ALGORITHM; BLOOD; DRUG EFFECT; HORMONE SUBSTITUTION; METHODOLOGY; MIDDLE AGED; ONSET AGE; ORAL DRUG ADMINISTRATION; REFERENCE VALUE; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE OF ONSET; AGED; ALGORITHMS; DOUBLE-BLIND METHOD; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; REFERENCE VALUES; RESEARCH DESIGN; SEXUAL BEHAVIOR; TESTOSTERONE; TREATMENT OUTCOME;

EID: 65549104191     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0634     Document Type: Article

References (41)

1. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros J-J, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W & Wu FCW. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. International Journal of Andrology 2005 28 125-127.
2. Bhasin S, Cunningham G, Hayes F, Matsumoto AM, Snyder PJ, Swerdloff RS & Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 1995-2010.
3. Laughlin GA, Barrett-Connor E & Bergstrom J. Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology and Metabolism 2008 93 68-75.
4. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ & Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999 84 2647-2653.
5. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG & Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999 84 1966-1972.
6. Kenny AM, Prestwood KM, Gruman CA, Marcello KM & Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with lowbioavailable testosterone levels. Journal of Gerontology 2001 56A M266-M272.
7. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R & the North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism 2003 88 2673-2681.
8. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P & Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. Journal of Gerontology 2003 58A 618-625.
9. Haren MT, Wittert GA, Chapman IM, Coates P & Morley JE. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005 50 124-133.
10. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ & Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Journal of Clinical Endocrinology and Metabolism 2004 89 503-510.
11. Page ST, Amory JK, Du Bois Bowman F, Anawalt BD, Matsumoto AM, Bremner WJ & Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Journal of Clinical Endocrinology and Metabolism 2005 90 1502-1510.
12. Bhasin S,Woodhouse L, Casaburi R, Singh AB, Phong Mac R, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov J, Magliano L & Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. Journal of Clinical Endocrinology and Metabolism 2005 90 678-688.
13. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, Smith GE, Khosla S & Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. New England Journal of Medicine 2006 355 1647-1659.
14. Emmelot-Vonk MH, Verhaar HJJ, Nakhai Pour HR, Aleman A, Lock TMTW, Bosch JLHR, Grobbee DE & van der Schouw Y. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men. Journal of the American Medical Association 2008 299 39-52.
15. Nieschlag E, Mauss J, Coert A & Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinologica 1975 79 366-374.
16. Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J & Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klinische Wochenschrift 1976 54 875-879.
17. Bagchus WM, Hust R, Maris F, Schnabel PG & Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 2003 23 319-325.
18. Houwing NS, Maris F, Schnabel PG & Bagchus WM. Pharmacokinetic study in women of three different doses of a new formulation of oral testosterone undecanoate, Andriol Testocaps. Pharmacotherapy 2003 23 1257-1265.
19. Schnabel PG, Bagchus W, Lass H, Thomsen T & Geurts TBP. The effect of food composition on serum testosterone levels after oral administration of Andriol® Testocaps®. Clinical Endocrinology 2007 66 579-585.
20. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D & Perry HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000 49 1239-1242.
21. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672.
22. Vermeulen A. Androgen replacement therapy in the aging male - a critical evaluation. Journal of Clinical Endocrinology and Metabolism 2001 86 2380-2390.
23. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C & Hummel W. A new 'Aging Males' Symptoms' rating scale. Aging Male 1999 2 105-114.
24. Derogatis LR. The Derogatis Interview for Sexual Functioning (DISF/ DISF-SR): an introductory report. Journal of Sex and Marital Therapy 1997 23 291-304.
25. Ware JE, Kosinski M & Keller SD. SF-36 Physical and Mental Health Summary Scales: a User's Manual, Revised 2nd Printing Boston MA (USA): The Health Institute, New England Medical Center, 1994.
26. Smith KW, Feldman HA & McKinlay JB. Construction and field evaluation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clinical Endocrinology 2000 53 703-711.
27. Heinemann LAJ, Saad F, Zimmermann T, Novak A, Myon E, Badia X, Potthoff P, T'Sjoen G, Pöllänen P, Goncharow NP, Kim S & Giroudet C. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health and Quality of Life Outcomes 2003 1 15.
28. T'Sjoen G, Goemaere S, De Meyere M & Kaufman JM. Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004 29 201-214.
29. Tsujimura A, Matsumiya K, Miyagawa Y, Takao T, Fujita K, Takada S, Koga M, Iwasa A, Takeyama M & Okuyama A. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. International Journal of Impotence Research 2005 17 259-263.
30. Miwa Y, Kaneda T & Yokoyama O. Correlation between the Aging Males' Symptoms scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. Journal of Sexual Medicine 2006 3 723-726.
31. Kratzik C, Heinemann LAJ, Saad F, Minh Thai D & Rücklinger E. Composite screener for androgen deficiency related to the Aging Males' Symptoms scale. Aging Male 2005 8 157-161.
32. Morley JE, Perry HM, Kevorkian RT & Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006 53 424-429.
33. Kratzik CW, Reiter WJ, Riedl AM, Lunglmayr G, Brandstätter N, Rüclinger E, Metka M & Huber J. Hormone profiles, body mass index and Aging Males' Symptoms: results of the androx vienna municipality study. Aging Male 2004 7 188-196.
34. Moore C, Huebler D, Zimmermann T, Heinemann LAJ, Saad F & Minh Thai D. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. European Urology 2004 46 80-87.
35. Heinemann LA, Moore C, Dinger JC & Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health and Quality of Life Outcomes 2006 4 23.
36. Reddy P, White CM, Dunn AB, Moyna NM & Thompson PD. The effect of testosterone on health-related quality of life in elderly males - a pilot study. Journal of Clinical Pharmacy and Therapeutics 2000 25 421-426.
37. Kenny AM, Bellantonio S, Gruman CA, Acosta RD & Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. Journal of Gerontology 2002 57A M321-M325.
38. Merza Z, Blumsohn A, Nah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F & Ross RJM. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology 2005 29 381-391.
39. Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 2008 100 170-183.
40. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P & Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 1997 82 1661-1667.
41. Kenny AM, Prestwood KM & Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocrine Research 2000 26 153-168.